Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A phase 2/3 trial of Gene-modified (GM) T cell therapy in advanced solid tumours, run by Celgene, now recruiting.
Overview
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells is a phase 2/3 interventional study registered as NCT03435796 by Celgene, with 1541 participants planned, started 2018-07-19 and due to reach its primary completion in 2036-11-30. Interventions recorded: Gene-modified (GM) T cell therapy.
Similar pages
not linked directly; found by shared links- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.